

An Academic Health Sciences Centre for London

Pioneering better health for all

King's Health Partners Clinical Trials Office
Amendment assessment form

Study Short Title:	
Chief Investigator:	
(Co)Sponsor(s):	
EudraCT Number:	
IRAS Number:	
MATTS Number:	

Amendment ID: (title or date etc.)

Justification: (Describe changes and reason for changes)

Implementation: (Give details on how the changes will be managed and implemented)

Documents that will change as a result of the amendment	
(list not exhaustive; other documents may require amendments which should be listed here)	

Documents that will	Current version & date	Amended version & date	
submitted			
Protocol			
B IB			
GP letter			
IMP labels			
Other Other			
Internal Trial Documents not for submission			
	🗌 Lab Manual	Source Data Location List	
Contracts	Pharmacy Documents	Statistical Analysis Plan	
🗌 Data Management Plan	Risk Assessment	Other (please specify):	
Monitoring Plan	Source Data Worksheets		
Substantiality Review:			
	Substantial	Non-Substantial	
MHRA			
REC			
HRA			
Competent Authority Data set (Completed in IRAS or EudraCT)			
Update required?	and will r	tes required but non-substantial not be submitted until next ial amendment.	

If multinational, countries for which CA info will be updated:		□ N/A
Parties to be notified of the am (list not exhaustive; there may be oth		
Pharmacy,	Data Managers	eCRF/Database Provider
Clinical Research Facility	External CTU/King's CTU	Randomisation Service
	ESMS/unblinding service	Labs
🗌 R&D	Contracts team	Other (please specify):
Matts Updated?		
☐ Yes	No (please justify):	

Clinical Research Associate preparing amendment:	Name:
Clinical Quality Manager or Delegate Authorisation:	Name: Signature:
	Date:

(Signed copy to be filed in KHP-CTO Sponsor file)



King's College Hospital

South London and Maudsley NHS Foundation Trust